Hematology Center, National Center for Children`s Health, 117984Beijing Children`s Hospital, Capital Medical University, Beijing, China.
Hematologic Disease Laboratory, National Center for Children's Health, 117984Beijing Children's Hospital, Capital Medical University, Beijing, China.
Int J Immunopathol Pharmacol. 2022 Jan-Dec;36:3946320221125591. doi: 10.1177/03946320221125591.
LPS-responsive beige-like anchor (LRBA) deficiency is one of the most common monogenic disorders causing common variable immunodeficiency (CVID) and CVID-like disorders. However, the clinical spectrum of compound heterozygous (CHZ) LRBA variation should be extended. In this study, we presented five cases of compound heterozygous LRBA with various refractory cytopenias.
Retrospective analysis of the clinical manifestations, management, and outcomes of five cases (from five pedigrees) with gene CHZ variants which initially manifested as single/multilineage immune cytopenias was performed.
Unlike homozygous mutations, compound heterozygous LRBA variation should always be kept in mind for the various phenotypes and different treatment responses.
LPS 反应性米色样锚定蛋白(LRBA)缺陷是引起常见可变免疫缺陷(CVID)和 CVID 样疾病的最常见单基因疾病之一。然而,复合杂合(CHZ)LRBA 变异的临床谱应该扩大。在本研究中,我们介绍了 5 例复合杂合 LRBA 伴多种难治性血细胞减少症的病例。
对 5 例(来自 5 个家系)患者的临床表现、治疗方法和结局进行回顾性分析,这些患者最初表现为单一/多谱系免疫性血细胞减少症,且携带 LRBA 基因 CHZ 变异。
与纯合突变不同,复合杂合 LRBA 变异应始终牢记各种表型和不同的治疗反应。